These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23469298)

  • 21. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India.
    Sarnoff R; Desai J; Desjeux P; Mittal A; Topno R; Siddiqui NA; Pandey A; Sur D; Das P
    Trop Med Int Health; 2010 Jul; 15 Suppl 2():42-9. PubMed ID: 20487423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seropositivity of Visceral leishmaniasis on people of VL endemic three districts of Nepal.
    Basnyat S; Banjara MR; Ghimire P; Matlashewski G; Singh A
    Parasitol Int; 2021 Feb; 80():102236. PubMed ID: 33147500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An assessment of a substitute or complement for inpatient and outpatient care of visceral leishmaniasis in Nepal.
    Adhikari SR
    J Vector Borne Dis; 2012 Dec; 49(4):242-8. PubMed ID: 23428524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
    Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
    Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral leishmaniasis in Nepal during 1980-2006.
    Joshi DD; Sharma M; Bhandari S
    J Commun Dis; 2006 Mar; 38(2):139-48. PubMed ID: 17370676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will visceral leishmaniasis be eliminated from Nepal? A review of recent (1994-2006) control efforts.
    Bhandari GP; Angdembe MR; Rijal S; Boelaert M
    Nepal Med Coll J; 2011 Sep; 13(3):220-5. PubMed ID: 22808821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
    Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan.
    Griekspoor A; Sondorp E; Vos T
    Health Policy Plan; 1999 Mar; 14(1):70-6. PubMed ID: 10351471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visceral leishmaniasis from a non-endemic Himalayan region of Nepal.
    Shrestha M; Pandey BD; Maharjan J; Dumre SP; Tiwari PN; Manandhar KD; Pun SB; Pandey K
    Parasitol Res; 2018 Jul; 117(7):2323-2326. PubMed ID: 29717371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An outbreak investigation of visceral leishmaniasis among residents of Dharan town, eastern Nepal, evidence for urban transmission of Leishmania donovani.
    Uranw S; Hasker E; Roy L; Meheus F; Das ML; Bhattarai NR; Rijal S; Boelaert M
    BMC Infect Dis; 2013 Jan; 13():21. PubMed ID: 23327548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: Expansion of visceral leishmaniasis to the western hilly part of Nepal.
    Pandey BD; Pun SB; Kaneko O; Pandey K; Hirayama K
    Am J Trop Med Hyg; 2011 Jan; 84(1):107-8. PubMed ID: 21212211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, India.
    Dial NJ; Medley GF; Croft SL; Mahapatra T; Priyamvada K; Sinha B; Palmer L; Terris-Prestholt F
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009129. PubMed ID: 33534836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A series of case reports of autochthonous visceral leishmaniasis, mostly in non-endemic hilly areas of Nepal.
    Pun SB; Pandey K; Shah R
    Am J Trop Med Hyg; 2013 Feb; 88(2):227-9. PubMed ID: 23249686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review.
    Sunyoto T; Boelaert M; Meheus F
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):57-69. PubMed ID: 30513027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economic burden of Kala-azar in households of the Danusha and Mahottari districts of Nepal.
    Adhikari SR; Maskay NM
    Acta Trop; 2003 Sep; 88(1):1-2. PubMed ID: 12943969
    [No Abstract]   [Full Text] [Related]  

  • 40. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
    Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
    Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.